Generic Medicine Info
Indications and Dosage
Early parkinsonism
Adult: As conventional preparation: 10 mg daily, either as a single dose (in the morning) or in 2 divided doses of 5 mg (at breakfast and lunchtime). As oral lyophilisate tab: Initially, 1.25 mg daily.

Adult: Initially, 6 mg daily, may increase in increments of 3 mg/24 hr every 2 weeks. Max: 12 mg/24 hr. Patches should be changed every 24 hours and new patch is applied to a different site. (Patient on doses ≥9 mg/24 hr should restrict intake of tyramine-rich foods during and for 2 weeks after treatment discontinuation.
Elderly: ≥65 yr 6 mg/24 hr.
Should be taken with food.
Active duodenal or gastric ulcer. Concomitant use w/ serotonin agonists (e.g. sumatriptan, zolmitriptan), pethidine and other opioids, antidepressants (including TCAs, MAOIs, SSRIs, serotonin norepinephrine reuptake inhibitors), St John’s wort.
Special Precautions
Patient w/ uncontrolled HTN, angina, arrhythmias, psychosis, history of peptic ulcer and those at risk of orthostatic hypotension. Severe hepatic or renal impairment. Elderly. Pregnancy and lactation.
Adverse Reactions
Orthostatic hypotension, chest pain, headache, confusion, tremor, vertigo, dizziness, depression, psychosis, hallucinations, agitation, nausea, vomiting, diarrhoea, constipation, dry mouth, sore throat, difficulty in micturition, skin reactions, muscle cramps, back and joint pain, myopathy; insomnia, abnormal dreams; transient elevations in liver enzymes; mouth ulcers, stomatitis.
PO/Transdermal: C
Patient Counseling Information
This drug may cause somnolence, if affected, do not drive or operate machinery.
Monitoring Parameters
Monitor BP, symptoms of parkinsonism, suicidal ideation, general mood and behaviour. Perform periodic skin examinations.
Symptoms: Ataxia, dizziness, tremor, irritability, pyrexia, convulsions, hypomania, psychosis, euphoria, resp depression, severe muscle spasms, hypotension, HTN, coma, extrapyramidal symptoms. Management: Symptomatic treatment.
Drug Interactions
May increase risk of hypertensive reactions w/ dopamine. May increase bioavailability w/ OCs or drugs for hormone replacement therapy.
Potentially Fatal: May cause severe serotonin syndrome w/ antidepressants (including TCAs, MAOIs, SSRIs, serotonin norepinephrine reuptake inhibitors), serotonin agonists (e.g. sumatriptan, zolmitriptan). May cause resp depression and hypotension w/ pethidine and other opioids.
Food Interaction
May cause severe serotonin syndrome w/ St John’s wort. May cause hypertensive crisis w/ tyramine-rich food and beverages. Increased sedative effects w/ alcohol.
Lab Interference
May cause false-positive reaction w/ urine detection of amphetamine/methamphetamine.
Description: Selegiline increases dopaminergic activity by intervening w/ the reuptake of dopamine at the synapse. It also irreversibly inhibits monoamine oxidase (MAO)-B which is involved in the metabolism of dopamine in the brain.
Onset: W/in 1 hr (oral).
Duration: 24-72 hr (oral).
Absorption: Readily absorbed from the GI tract. Bioavailability: Approx 10%. Time to peak plasma concentration: 30 min (oral conventional preparation).
Distribution: Rapidly distributed throughout the body; crosses the blood-brain barrier. Plasma protein binding: Up to 94%.
Metabolism: Undergoes extensive first-pass metabolism; converted to at least 5 metabolites including l-(-)-desmethylselegiline (norselegiline), l-(-)-N-methylamfetamine and l-(-)-amfetamine.
Excretion: Mainly via urine, as metabolites; faeces (approx 15%). Elimination half-life: 10 hr (oral); 18-25 hr (transdermal).
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Selegiline, CID=26757, (accessed on Jan. 23, 2020)

Store between 20-25°C.
MIMS Class
Antiparkinsonian Drugs
ATC Classification
N04BD01 - selegiline ; Belongs to the class of dopaminergic agents, monoamine oxidase B inhibitors. Used in the management of Parkinson's disease.
Anon. Selegiline. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 04/02/2016.

Buckingham R (ed). Selegiline Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 04/02/2016.

EMSAM patch (Mylan Specialty). DailyMed. Source: U.S. National Library of Medicine. Accessed 04/02/2016.

Joint Formulary Committee. Selegiline Hydrochloride. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 04/02/2016.

McEvoy GK, Snow EK, Miller J et al (eds). Selegiline Hydrochloride. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). Accessed 04/02/2016.

Preston CL (ed). Selegiline + Oxycodone. Stockley’s Drug Interactions [online]. London. Pharmaceutical Press. Accessed 04/02/2016.

Preston CL (ed). Selegiline + Pethidine. Stockley’s Drug Interactions [online]. London. Pharmaceutical Press. Accessed 04/02/2016.

Preston CL (ed). Zolmitriptan + Selegiline. Stockley’s Drug Interactions [online]. London. Pharmaceutical Press. Accessed 04/02/2016.

Selegiline Hydrochloride Capsule (Apotex Corp.). DailyMed. Source: U.S. National Library of Medicine. Accessed 04/02/2016.

Zelapar (Selegiline Hydrochloride) Orally Disintegrating Tablets. U.S. FDA. Accessed 04/02/2016.

Disclaimer: This information is independently developed by MIMS based on Selegiline from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in